Investors Research Corp Tcr2 Therapeutics Inc. Transaction History

Investors Research Corp

  • $446 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 29, 2021
BUY
$16.41 - $24.71 $246 - $370
15 New
15 $0
Q4 2020

Jan 21, 2021
SELL
$19.0 - $32.63 $1,311 - $2,251
-69 Closed
0 $0
Q3 2020

Oct 20, 2020
BUY
$13.1 - $20.69 $903 - $1,427
69 New
69 $1,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Investors Research Corp Portfolio

Follow Investors Research Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Investors Research Corp, based on Form 13F filings with the SEC.

News

Stay updated on Investors Research Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email